|
| 36268860 | The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use. | Nucleic Acids Res | 2023 |
| 37017629 | HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies. | J Med Chem | 2023 |
| 37017629 | HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies. | J Med Chem | 2023 |
| 37403870 | Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes. | J Med Chem | 2023 |
| 36624665 | canSAR: update to the cancer translational research and drug discovery knowledgebase. | Nucleic Acids Res | 2023 |
| 36549590 | Native Size-Exclusion Chromatography-Based Mass Spectrometry Reveals New Components of the Early Heat Shock Protein 90 Inhibition Response Among Limited Global Changes. | Mol Cell Proteomics | 2023 |
| 34954130 | Enhancing access to innovative cancer drugs: Cross-sector consensus on a way forward to benefit patients. | Drug Discov Today | 2022 |
| 36545432 | The era of high-quality chemical probes. | RSC Med Chem | 2022 |
| 33219674 | canSAR: update to the cancer translational research and drug discovery knowledgebase. | Nucleic Acids Res | 2021 |
| 33771354 | A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2. | Trends Pharmacol Sci | 2021 |
| 33521702 | Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity. | Cell Rep Med | 2021 |
| 33762744 | Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. | Nat Rev Clin Oncol | 2021 |
| 35211674 | Target 2035 - update on the quest for a probe for every protein. | RSC Med Chem | 2021 |
| 34753775 | HER3 Is an Actionable Target in Advanced Prostate Cancer. | Cancer Res | 2021 |
| 34795259 | Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. | Nat Commun | 2021 |
| 34077750 | Evolution of kinase polypharmacology across HSP90 drug discovery. | Cell Chem Biol | 2021 |
| 31778323 | Public resources for chemical probes: the journey so far and the road ahead. | Future Med Chem | 2021 |
| 32161100 | CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells. | Cancer Res | 2020 |
| 32066817 | The kinase polypharmacology landscape of clinical PARP inhibitors. | Sci Rep | 2020 |
| 32006467 | From patent to patient: analysing access to innovative cancer drugs. | Drug Discov Today | 2020 |
| 32094403 | Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. | Oncogene | 2020 |
| 31879968 | Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. | Hepatology | 2020 |
| 32965646 | Correction to: Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective. | Adv Exp Med Biol | 2020 |
| 32994435 | Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches. | Sci Rep | 2020 |
| 33016930 | Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. | J Clin Invest | 2020 |
| 32645016 | Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. | PLoS One | 2020 |
| 32297218 | Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective. | Adv Exp Med Biol | 2020 |
| 32427987 | Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. | Oncogene | 2020 |
| 30664779 | Small-molecule targeting of brachyury transcription factor addiction in chordoma. | Nat Med | 2019 |
| 31296956 | Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. | Oncogene | 2019 |
| 31409651 | Structural and functional characterisation of human RNA helicase DHX8 provides insights into the mechanism of RNA-stimulated ADP release. | Biochem J | 2019 |
| 31284790 | Transforming cancer drug discovery with Big Data and AI. | Expert Opin Drug Discov | 2019 |
| 31150022 | Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'. | Nat Rev Clin Oncol | 2019 |
| 30733593 | Challenges to curing primary brain tumours. | Nat Rev Clin Oncol | 2019 |
| 31113841 | Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. | Clin Cancer Res | 2019 |
| 30905967 | Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer. | Oncogene | 2019 |
| 30496479 | canSAR: update to the cancer translational research and drug discovery knowledgebase. | Nucleic Acids Res | 2019 |
| 30602624 | Correction: <i>In vitro</i> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors. | Cancer Res | 2019 |
| 30602624 | Correction: <i>In vitro</i> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors. | Cancer Res | 2019 |
| 30602623 | Correction: Silencing of HSP90 Cochaperone AHA1 Expression Decreases Client Protein Activation and Increases Cellular Sensitivity to the HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin. | Cancer Res | 2019 |
| 29063678 | Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor. | Mol Oncol | 2018 |
| 30173339 | Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. | Cancer Chemother Pharmacol | 2018 |
| 30613326 | Privileged Structures and Polypharmacology within and between Protein Families. | ACS Med Chem Lett | 2018 |
| 29391353 | HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target. | Clin Cancer Res | 2018 |
| 29472484 | Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. | Science | 2018 |
| 29662167 | Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. | Nat Genet | 2018 |
| 29329780 | Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling. | Cell Signal | 2018 |
| 29249694 | Objective, Quantitative, Data-Driven Assessment of Chemical Probes. | Cell Chem Biol | 2018 |
| 29240418 | Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766). | J Med Chem | 2018 |
| 29113809 | MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. | Gastroenterology | 2018 |